NYU

Artios Pharma Bolsters Board of Directors with Appointment of Chris Liu, PhD

Retrieved on: 
Tuesday, April 9, 2024
Biotechnology, Kite, Business, Business administration, Patient, Research, DNA, Fudan University, Acquisition, NYU, MBA, Doctor of Philosophy, DDR, Master of Business Administration, Therapy, Drug development, Investment, RTW

CAMBRIDGE, United Kingdom and NEW YORK, April 09, 2024 (GLOBE NEWSWIRE) -- Artios Pharma Limited (“Artios”), clinical-stage biotech company led by pioneers of DNA damage response (“DDR”) drug development, announces the appointment of Chris Liu, Ph.D., Senior Research Analyst specializing in oncology at RTW Investments, LP (“RTW”), to its Board of Directors.

Key Points: 
  • CAMBRIDGE, United Kingdom and NEW YORK, April 09, 2024 (GLOBE NEWSWIRE) -- Artios Pharma Limited (“Artios”), clinical-stage biotech company led by pioneers of DNA damage response (“DDR”) drug development, announces the appointment of Chris Liu, Ph.D., Senior Research Analyst specializing in oncology at RTW Investments, LP (“RTW”), to its Board of Directors.
  • Niall Martin, Chief Executive Officer of Artios, said: “We are delighted to welcome Chris, a prominent research analyst to our Board of Directors.
  • Chris Liu, Ph.D. Board Director of Artios, added: “RTW is now a top shareholder of Artios following the acquisition of Arix and the expansion of our equity interest, which reflects both our confidence and excitement in Artios’ innovative platform targeting broad aspects of the DNA damage response.
  • He currently serves on the board of NiKang Therapeutics, Oricell Therapeutics and Nuance Pharma as a Board Director or Observer.

TELA Bio Welcomes Acclaimed Surgeon as Vice President of Medical Affairs and Surgeon Strategy

Retrieved on: 
Monday, April 8, 2024
Surgeon, Plastic, Associate, Education, Matrix, National Cancer Institute, Bellevue Hospital, MD Anderson Cancer Center, NYU, University, General surgery, Surgical oncology, Health, FACS, Dentistry

MALVERN, Pa., April 08, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced Howard N. Langstein, MD, FACS, as Vice President of Medical Affairs and Surgeon Strategy.

Key Points: 
  • MALVERN, Pa., April 08, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced Howard N. Langstein, MD, FACS, as Vice President of Medical Affairs and Surgeon Strategy.
  • Dr. Langstein is the former Chief of Plastic and Reconstructive Surgery at the University of Rochester Medical Center, known for his extensive expertise, especially in microvascular reconstruction and innovative approaches to complex surgical problems.
  • “With more than 30 years of experience in plastic and reconstructive surgery, I understand the needs and challenges in this space,” said Dr. Langstein.
  • "We are thrilled to welcome Dr. Langstein to our team," said Paul Talmo, Chief Technology Officer of TELA Bio.

ReShape Lifesciences® Reports Year Ended December 31, 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Monday, April 1, 2024
Commitment, Research, Obesity, PTE, Exercise, Bariatrics, Patent, Patient, Food and Drug Administration, Weight loss, Travel, Acquisition, FLEX, Prescription, NYU, Food, Security (finance), Insurance, Marketing, Surgeon, C-peptide, Annual report, PMA, NYU Langone Health, Division, United States patent law, FDA, Advertising, Bariatric surgery

IRVINE, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today reported financial results for the fourth quarter and fiscal year ended December 31, 2023 and provided a corporate strategic update.

Key Points: 
  • Specifically, it received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for patent application 18/370,819.
  • December 2023: Engaged Maxim Group LLC, to act as the company’s exclusive financial advisor to help identify potential synergistic merger and acquisition partnerships.
  • December 2023: Received U.S. Food and Drug Administration (FDA) PMA supplement approval for its next-generation Lap-Band® 2.0 FLEX, designed to improve the patient experience.
  • Participants using this feature are requested to dial into the conference call fifteen minutes ahead of time to avoid delays.

Heritage Capital Group Appoints Joseph Lemieux, Jr. and Oren Schmidt to Lead Aerospace and Defense Industry Team

Retrieved on: 
Tuesday, April 9, 2024
Teleflex, University of Chicago, Growth, A&D, MRO, Acquisition, University, NYU, Westfield State University, MBA, Marmon Group, Heritage, Long Island University, FINRA, Berkshire Hathaway, Management

Their extensive experience will enhance Heritage Capital Group's capabilities in the A&D sector.

Key Points: 
  • Their extensive experience will enhance Heritage Capital Group's capabilities in the A&D sector.
  • Joseph brings over 27 years of leadership in the A&D industries, starting his career in business development at Teleflex Inc. in 1997.
  • He later co-founded Aero-Hose, Corp., a niche value-added manufacturing company focused on fluid conveyance assemblies across commercial, military, and space markets.
  • Heritage Capital Group is a FINRA registered broker-dealer, and a member of Oaklins, the world's most experienced mid-market M&A advisor, with 850 professionals globally and dedicated industry teams in 45 countries worldwide.

Leading Cardiologists from NYU Langone Heart Present Latest Clinical Findings & Research at American College of Cardiology 73rd Annual Scientific Session

Retrieved on: 
Friday, April 5, 2024
Diagnosis, Internal medicine, Ozone, Cardiovascular disease, Eugene Braunwald, System, N95, Blood, Digital, Assistant, Memory, Risk, Diabetes, Inflammation, Patient, Biomarker, Research, Moyamoya disease, Cardiovascular Research, Splenic infarction, NYU, Ischemia, IMR, Particulates, Woman, Heart failure, American College, MPH, CFR, NYU Langone Health, EHR, American Red Cross, Bangladesh Technical Education Board, Air pollution, Data, Osteoarthritis, ACC, CCD, Work, Physician, Medical device

NEW YORK, April 5, 2024 /PRNewswire/ -- Experts from NYU Langone Heart are presenting their latest clinical findings and research discoveries during the American College of Cardiology (ACC) 2024 Annual Scientific Session & Expo, held April 6 to 8 in Atlanta.

Key Points: 
  • NEW YORK, April 5, 2024 /PRNewswire/ -- Experts from NYU Langone Heart are presenting their latest clinical findings and research discoveries during the American College of Cardiology (ACC) 2024 Annual Scientific Session & Expo, held April 6 to 8 in Atlanta.
  • "The ACC conference serves as a place for our faculty to explore, learn, and share all the latest advancements in the field.
  • They will also be available for media interviews to discuss innovative and noteworthy scientific developments emerging from the conference.
  • Her research is focused on understanding what makes heart attacks in women unique and the best methods of detection and treatment.

Praxis Precision Medicines to Host PRAX-628 Program Update

Retrieved on: 
Monday, March 25, 2024
Praxis, Neurology, Epilepsy, NYU, Central nervous system, CNS

BOSTON, March 25, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that it will host a virtual program update to discuss its PRAX-628 program in epilepsy on Tuesday, March 26, 2024 at 8:00 a.m. ET. To register, click here.

Key Points: 
  • Presentation will be held virtually on Tuesday, March 26, 2024 at 8:00 a.m.
  • ET
    Praxis leadership will be joined by key opinion leader in epilepsy Dr. Daniel Friedman, Professor of Neurology at NYU Grossman School of Medicine
    BOSTON, March 25, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that it will host a virtual program update to discuss its PRAX-628 program in epilepsy on Tuesday, March 26, 2024 at 8:00 a.m.
  • ET.
  • To register, click here .

CData Software Acquires Data Virtuality to Modernize Data Virtualization for the Enterprise

Retrieved on: 
Thursday, April 4, 2024
Professional Services, Data Management, Data Analytics, Technology, Software, Networks, Internet, Cloud, BSH, Organization, Growth, Acquisition, NYU, Global 2000, Driver, Fortune 500, CDATA, Data management, SME, Virtual reality, Cryptocurrency

CData Software , a leading provider of data connectivity solutions, today announced the acquisition of Data Virtuality , a global provider of data integration and management solutions.

Key Points: 
  • CData Software , a leading provider of data connectivity solutions, today announced the acquisition of Data Virtuality , a global provider of data integration and management solutions.
  • CData is the only data management vendor to bring a bi-modal integration stack to market, allowing customers to leverage both data replication and live data access within one common connectivity platform.
  • Now, Data Virtuality expands CData’s ability to support organizations with an enterprise-grade data virtualization platform that solves for organization-wide access to live data.
  • “Data Virtuality is proud to share CData’s commitment to empowering businesses to unleash and maximize the full potential of their data,” said Dr. Nick Golovin, founder and CEO of Data Virtuality.

egnite, Inc. Announces the Appointment of Vinod Thourani and Nicholas Amoroso to Its Medical Advisory Board

Retrieved on: 
Tuesday, March 26, 2024
Technology, Medical Devices, Health Technology, Cardiology, Software, Practice Management, Managed Care, Health, Artificial Intelligence, Bernard Marcus, International Society, Coronary artery disease, Partnership, George Washington University, Patient, Research, Cardiac catheterization, NYU, Treasurer, MD, Society, Amoroso, Medical school, Vinod, Physician, Pharmaceutical industry

egnite, Inc. , a leading digital health company specializing in cardiovascular care, today announced the addition of two distinguished physicians, Vinod H. Thourani, MD and Nicholas Amoroso, MD, to its Medical Advisory Board .

Key Points: 
  • egnite, Inc. , a leading digital health company specializing in cardiovascular care, today announced the addition of two distinguished physicians, Vinod H. Thourani, MD and Nicholas Amoroso, MD, to its Medical Advisory Board .
  • His involvement in novel clinical trials and contributions to leading cardiology research brings a wealth of experience to egnite’s medical advisory board.
  • "We are honored to welcome Vinod and Nick to egnite’s Medical Advisory Board," said Joel Portice, president and CEO of egnite.
  • The appointment of Thourani and Amoroso to its Medical Advisory Board underscores egnite’s commitment to excellence and advancement in developing solutions to address the evolving needs of cardiovascular patients and providers.

Synthekine Announces U.S. FDA Clearance of IND Application for CD19 CAR-T and Orthogonal IL-2 Combination Therapy, SYNCAR-001 + STK-009, for Treatment of Lupus Without Lymphodepletion

Retrieved on: 
Tuesday, March 26, 2024
Biotechnology, FDA, Health, Pharmaceutical, Clinical Trials, LN, Risk, Patient, NYU, SLE, IND, Investigational New Drug, Safety, Lupus nephritis, Inc., CD19, Food, Medicine, Pharmaceutical industry

SYNCAR-001 + STK-009 is a cytokine-inducible cell therapy regimen built on Synthekine’s proprietary orthoIL-2 technology.

Key Points: 
  • SYNCAR-001 + STK-009 is a cytokine-inducible cell therapy regimen built on Synthekine’s proprietary orthoIL-2 technology.
  • The SYNCAR-001 + STK-009 combination therapy is in a Phase 1 study ( NCT05665062 ) in CD19+ hematologic malignancies.
  • “However, successful treatment with CD19 CAR-Ts requires patients to be lymphodepleted, a significant burden on the patient, physician and healthcare system.
  • By leveraging Synthekine’s orthoIL-2 technology, STK-009 has the potential to drive SYNCAR-001 cell engraftment and controlled cell expansion without lymphodepletion.

Enterprise Ethereum Alliance Announces New Leadership and Vision

Retrieved on: 
Tuesday, March 19, 2024
Technology, Finance, Consulting, Banking, Other Technology, Professional Services, Software, Blockchain, Internet, Other Professional Services, Ethereum, Momentum, Microsoft, EVM, NYU, EY, EEA, Decentralized finance, Scarbrough, Chairperson, Ecosystem, Multimedia, Privacy, ETF, Cryptocurrency

The Enterprise Ethereum Alliance (EEA) , the leading global community for enterprise blockchain, today announced the appointment of new leadership and a renewed vision for the future of the alliance at the intersection of the Ethereum ecosystem and enterprise.

Key Points: 
  • The Enterprise Ethereum Alliance (EEA) , the leading global community for enterprise blockchain, today announced the appointment of new leadership and a renewed vision for the future of the alliance at the intersection of the Ethereum ecosystem and enterprise.
  • Rhodes expressed the goals for the convening, which showcased the latest developments and innovations in the Ethereum for enterprise blockchain space, as well as to foster collaboration and engagement among the EEA community.
  • Rhodes praised Paul, Karen and Vanessa for their expertise, vision, and dedication to the EEA and the enterprise blockchain industry.
  • The EEA is the industry's leading global community for enterprise blockchain working with an open, standards-based architecture and specification to accelerate the adoption of Enterprise Ethereum.